SIGIRR has also been reported to inhibit Th17 cell proliferation by counteracting IL-1 signaling and glycolytic metabolism, outcome of critical significance in regard to the development of spontaneous colitis observed in IL-10 KO mice, in which Th17 cells greatly contribute to disease pathology (73). The gene discussed is IL1B; the disease is colitis.